Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 23 citing articles:

Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status
Andrea Sansone, Eugenia Guida, Susanna Dolci, et al.
Basic and Clinical Andrology (2025) Vol. 35, Iss. 1
Open Access | Times Cited: 1
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis
Στέργιος Σουλαϊδόπουλος, Dimitrios Terentes‐Printzios, Nikolaos Ioakeimidis, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2024) Vol. 10, Iss. 5, pp. 403-412
Open Access | Times Cited: 5
Application of terahertz Time-Domain spectroscopy and chemometrics-based whale optimization algorithm in PDE5 inhibitor detection
Aolin Zhang, Ge Qin, Jifen Wang, et al.
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy (2024) Vol. 310, pp. 123894-123894
Closed Access | Times Cited: 4
Hallmarks of aging: middle-aging hypovascularity, tissue perfusion and nitric oxide perspective on healthspan
Teow J. Phua
Frontiers in Aging (2025) Vol. 5
Open Access
Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health
Robert A. Kloner, Arthur L. Burnett, Martin Miner, et al.
The Journal of Sexual Medicine (2023) Vol. 21, Iss. 2, pp. 90-116
Open Access | Times Cited: 10
The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction
Robert A. Kloner, Eric J. Stanek, Karishma Desai, et al.
Clinical Cardiology (2024) Vol. 47, Iss. 2
Open Access | Times Cited: 3
Low-dose naltrexone extends healthspan and lifespan in C. elegans via SKN-1 activation
Weisha Li, Rebecca L. McIntyre, Bauke V. Schomakers, et al.
iScience (2024) Vol. 27, Iss. 6, pp. 109949-109949
Open Access | Times Cited: 2
Differences in ocular adverse events associated with phosphodiesterase-5 inhibitors: a real-world pharmacovigilance study
Guixiang Chen, Li Zhang, Siting Zhao, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 877-884
Closed Access | Times Cited: 2
Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis
Young Eun Shin, Sirikan Rojanasarot, Ana L. Hincapie, et al.
Sexual Medicine (2023) Vol. 11, Iss. 5
Open Access | Times Cited: 5
Association between prescription drugs and all-cause mortality risk in the UK population
Jonas Morin, Yves Rolland, Heike A. Bischoff‐Ferrari, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Adult-onset testosterone deficiency: the usefulness of hormone replacement in reducing mortality in men with this common age-related condition
Amar Mann, Richard C. Strange, Geoffrey Hackett, et al.
(2024) Vol. 1, Iss. 3, pp. 83-99
Closed Access | Times Cited: 1
Proceedings of PRINCETON IV: PDE5 inhibitors and cardiac health symposium
Raymond C. Rosen, Martin Miner, Arthur L. Burnett, et al.
Sexual Medicine Reviews (2024) Vol. 12, Iss. 4, pp. 681-709
Closed Access | Times Cited: 1
Association between prescription drugs and all‐cause mortality risk in the UK population
Jonas Morin, Yves Rolland, Heike A. Bischoff‐Ferrari, et al.
Aging Cell (2024) Vol. 23, Iss. 12
Open Access | Times Cited: 1
Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia
Dietrich Jehle, Raheed Sunesra, Hamza Uddin, et al.
The American Journal of Medicine (2024)
Closed Access | Times Cited: 1
Cardiovascular safety of testosterone replacement therapy (TRAVERSE trial)
Geoff Hackett, Michael Kirby
Trends in Urology & Men s Health (2024) Vol. 15, Iss. 4, pp. 2-6
Open Access
Counterfeiting honey with phosphodiesterase inhibitors for sexual activity enhancement: detection using high-performance liquid chromatography coupled with a photodiode array detector (HPLC-PAD)
Abdullah M. Alkhalaf, Fouza Alenazi, Mubarak Abudahash, et al.
Journal of Men s Health (2024) Vol. 20, Iss. 4, pp. 94-94
Open Access
Long Term Cardiovascular Safety of Testosterone Therapy: A Review of the TRAVERSE Study
Geoffrey Hackett
The World Journal of Men s Health (2024) Vol. 42
Open Access
Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia
Dietrich VK Jehle, Raheed Sunesra, Hamza Uddin, et al.
(2024)
Closed Access
Improvement in Endothelial Function in Men Taking Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction
Alex Konstantinovsky, Nina Kuchersky, Khalaf Kridin, et al.
The American Journal of Medicine (2023) Vol. 136, Iss. 10, pp. 1041-1043
Closed Access | Times Cited: 1
A potential role for pharmacological phosphodiesterase 5 inhibitors in the treatment of obstructive sleep apnea
Lisa A. Gottlieb
Journal of Cardiovascular Pharmacology (2023) Vol. 84, Iss. 1, pp. 32-33
Open Access
Low-dose Naltrexone (LDN) extends healthspan and lifespan through activation of the transcription factor SKN-1/NRF2 in C. elegans.
Weisha Li, Rebecca L. McIntyre, Bauke V. Schomakers, et al.
Research Square (Research Square) (2023)
Open Access
The increasing role of PDE5Is in men with diabetes and cardiovascular disease
Geoff Hackett, Mike Kirby
Trends in Urology & Men s Health (2023) Vol. 14, Iss. 4, pp. 2-7
Open Access
Erectile dysfunction drugs are essential and probably life-saving and should be provided to all men who need them just as birth control should be provided to all women who need them
Luke Curtis
International Journal of Impotence Research (2023) Vol. 36, Iss. 5, pp. 537-538
Closed Access
Page 1

Scroll to top